Search

everythinglearnresearchcommunity

for

Search:↓

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

The combination of encorafenib and binimetinib caused few skin issues.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Nilotinib can cause skin issues like red bumps and hair loss.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

MK-5108 is safe and shows potential against tumors, especially alone.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.